Abdulah Albreej Zainulabdin Abdulnabi, Dehghan Gholamreza, Nourazarian Alireza, Aslanabadi Naser, Assadi Jamshid
Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
Department of Basic Medical Sciences, Khoy University of Medical Sciences, Khoy, Iran.
Front Cardiovasc Med. 2025 Apr 4;12:1562234. doi: 10.3389/fcvm.2025.1562234. eCollection 2025.
Managing acute coronary syndrome (ACS) remains a major global healthcare concern. Identifying novel biomarkers is crucial to improving early detection and patient classification. Traditional markers such as cardiac troponins have limitations, including delayed detectability in blood samples, necessitating the search for better alternatives. Asprosin and angiopoietin-like protein 8 (ANGPTL8) have recently emerged as potential biomarkers for ACS diagnosis.
This comparative study included 100 participants, equally divided into ACS patients and healthy controls with matched demographics. Enzyme-linked immunosorbent assay (ELISA) was employed to quantify asprosin concentrations, while real-time polymerase chain reaction (RT-PCR) assessed ANGPTL8 gene expression levels. Receiver operating characteristic (ROC) curve analysis evaluated the diagnostic utility of these biomarkers, and Spearman's correlation was used to examine relationships between variables.
Asprosin levels were significantly elevated in ACS patients (5.27 ± 0.67 ng/ml) compared to healthy individuals (3.82 ± 1.20 ng/ml, < 0.001). ROC analysis demonstrated high diagnostic performance, with an area under the curve (AUC) of 0.95, 94% detection accuracy, and 85% precision in true negative identification. Similarly, ANGPTL8 expression was markedly increased ( < 0.001), showing an AUC of 0.83, 88% detection accuracy, and 64% specificity. A strong positive correlation was observed between asprosin and ANGPTL8 ( = 0.795, < 0.0001).
The findings highlight the potential of asprosin and ANGPTL8 as promising diagnostic and prognostic markers for ACS. Their high sensitivity and correlation suggest a complementary role in early ACS detection. However, further clinical trials are required to validate these biomarkers in broader patient populations and determine their practical implementation in medical settings.
Asprosin and ANGPTL8 exhibit strong diagnostic potential in ACS detection, potentially improving early intervention strategies. Future studies should focus on their integration into clinical practice for enhanced patient outcomes.
急性冠状动脉综合征（ACS）的管理仍然是全球医疗保健的主要关注点。识别新型生物标志物对于改善早期检测和患者分类至关重要。传统标志物如心肌肌钙蛋白存在局限性，包括血液样本中检测延迟，因此需要寻找更好的替代物。Asprosin和血管生成素样蛋白8（ANGPTL8）最近已成为ACS诊断的潜在生物标志物。
这项比较研究纳入了100名参与者，平均分为ACS患者和人口统计学匹配的健康对照组。采用酶联免疫吸附测定（ELISA）定量Asprosin浓度，同时通过实时聚合酶链反应（RT-PCR）评估ANGPTL8基因表达水平。受试者工作特征（ROC）曲线分析评估了这些生物标志物的诊断效用，并使用Spearman相关性检验变量之间的关系。
与健康个体（3.82±1.20 ng/ml，<0.001）相比，ACS患者的Asprosin水平显著升高（5.27±0.67 ng/ml）。ROC分析显示出高诊断性能，曲线下面积（AUC）为0.95，检测准确率为94%，真阴性识别精度为85%。同样，ANGPTL8表达明显增加（<0.001），AUC为0.83，检测准确率为88%，特异性为64%。Asprosin与ANGPTL8之间观察到强正相关（=0.795，<0.0001）。
研究结果突出了Asprosin和ANGPTL8作为ACS有前景的诊断和预后标志物的潜力。它们的高敏感性和相关性表明在ACS早期检测中具有互补作用。然而，需要进一步的临床试验在更广泛的患者群体中验证这些生物标志物，并确定它们在医疗环境中的实际应用。
Asprosin和ANGPTL8在ACS检测中表现出强大的诊断潜力，可能改善早期干预策略。未来的研究应侧重于将它们整合到临床实践中以提高患者预后。
